xamoterol has been researched along with nabumetone in 1 studies
| Studies (xamoterol) | Trials (xamoterol) | Recent Studies (post-2010) (xamoterol) | Studies (nabumetone) | Trials (nabumetone) | Recent Studies (post-2010) (nabumetone) |
|---|---|---|---|---|---|
| 269 | 80 | 17 | 393 | 105 | 60 |
| Protein | Taxonomy | xamoterol (IC50) | nabumetone (IC50) |
|---|---|---|---|
| Cytochrome P450 1A2 | Homo sapiens (human) | 5 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 1.868 | |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | 0.998 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.868 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
1 other study(ies) available for xamoterol and nabumetone
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |